: Metal-based complexes contribute a vital part to the available arsenal of cytotoxic agents today [...].
Metal-Based Complexes in Cancer Treatment / Gamberi T.; Hanif M.. - In: BIOMEDICINES. - ISSN 2227-9059. - ELETTRONICO. - 10:(2022), pp. 2573.1-2573.3. [10.3390/biomedicines10102573]
Metal-Based Complexes in Cancer Treatment
Gamberi T.;
2022
Abstract
: Metal-based complexes contribute a vital part to the available arsenal of cytotoxic agents today [...].
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
biomedicines-10-02573.pdf
accesso aperto
Descrizione: Metal-based complexes contribute a vital part to the available arsenal of cytotoxic agents today. Platinum(II) complexes, specifically targeting genomic DNA (e.g., cisplatin, carboplatin, and oxaliplatin), are widely used in the clinic to treat various cancers. Nearly 50% of cancer patients, who undergo chemotherapy, receive a platinum drug either alone or in combination therapy. Despite their central role in cancer chemotherapy, platinum drugs suffer serious drawbacks such as the limited spectrum of antitumor activities, systemic dose-related toxicity, and the frequent induction of drug resistance, often leading to treatment failure. These observations have prompted a strong interest in the investigation of nonplatinum metal-based drugs as an effective alternative. Several other platinum and nonplatinum metal complexes (e.g., Ti, Pd, Ru, Au) have shown potent cytotoxic and antitumor effects. Unlike platinum drugs, these often rely on DNA-independent biochemical mechanisms such as targeting tumor-associated proteins and induction of immunogenic antitumor properties for their therapeutic effects. Notably, a few of these drugs
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
185.58 kB
Formato
Adobe PDF
|
185.58 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
